---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106533"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:28:43.462372+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Atara Q2 net income $2.4M; tab-cel BLA accepted with Jan 10, 2026 PDUFA date

## Summary
- Cash, equivalents and short-term investments $22.3M at June 30, up from $13.8M at March 31.
- Net income $2.4M ($0.19 diluted EPS) vs. net loss prior year; revenues $17.6M, down from $28.6M.
- FDA accepted tab-cel BLA with Priority Review; PDUFA goal date January 10, 2026.
- Completed transfer of substantially all tab-cel activities to Pierre Fabre; $40M milestone due on FDA approval.
- Full-year 2025 operating expenses expected to decrease at least 60% vs 2024; strategic options evaluation resumed.

## SEC filing metadata
- accession: 0000950170-25-106533
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017025106533/0000950170-25-106533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017025106533/atra-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106533
- JSON: https://secwatch.observer/filing/0000950170-25-106533.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106533.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.